Here's Why Shares in USA Rare Earth Slumped 23% in June

USA Rare Earth shares fell 23% in June, driven by (1) an S-3/A SEC filing that could enable resale of 93,822,662 shares (35.2% of diluted common stock), (2) China adding the company to a restricted-access list as part of export controls that may disrupt rare-earth magnet supply chains, and (3) an MP Materials lawsuit alleging proprietary-technology theft. The combined dilution risk, supply-chain uncertainty, and litigation distraction increase near-term execution risk even though the long-term domestic rare-earth and magnet demand case remains.

Analysis

USAR is behaving like a classic pre-commerciality equity where the stock is more sensitive to financing structure than to near-term operating news. The 93.8mm-share resale registration creates an overhang that can suppress valuation even if no stock is sold immediately, because investors discount any rally as exit liquidity for earlier, lower-cost holders. In a capital-intensive buildout, that matters more than in a mature miner: it raises the equity cost of capital, which in turn can force more dilution or slower project pacing.

The China restrictions are a second-order negative because they don’t just limit sourcing; they complicate the path to a non-China supply chain for tooling, components, and process know-how. That is most damaging over the next 6-18 months, when execution risk is highest and every delay pushes monetization further out. MP is the cleaner relative beneficiary only because it has more scale and market credibility, not because it is immune; both names face the same geopolitical tailwind, but USAR has less margin for error.

The legal dispute is less about the lawsuit itself and more about partnership optionality: OEMs, defense buyers, and strategic investors tend to pause when IP ownership is contested. Consensus may be underappreciating how these three negatives reinforce each other—supply overhang lowers the share price, which worsens dilution optics just as operational uncertainty rises. The contrarian bull case is that blacklisting and litigation could accelerate a policy-driven funding solution, but that is a months-long catalyst, not a days-long one.

Key Decisions for Investors

• Short USAR outright on any relief rally over the next 2-6 weeks; use strength into volume spikes as entry. Thesis is that the resale overhang keeps a ceiling on the stock until the market sees who actually monetizes, with downside toward prior financing levels if selling pressure appears.
• Pair trade: long MP / short USAR for 1-3 months. MP still carries China-related friction, but it is the higher-quality rare-earth proxy with better scale, making USAR the weaker balance-sheet and execution leg if the domestic magnet theme remains in favor.
• If borrow is tight, buy USAR 3-6 month put spreads rather than naked shorts. The cleanest catalyst path is either an equity-funding announcement, a quarterly update showing slower-than-expected production ramp, or evidence of resale registration becoming effective; these events would pressure the stock without needing a broad market selloff.
• Set an upside risk trigger: if USAR announces a strategic JV, DOE/DoD funding, or non-China supply contract that materially reduces import dependence, cover shorts. That would invalidate the financing-overhang thesis by improving both credibility and funding runway.
• Avoid chasing MP long exposure solely on the blacklist headline; relative outperformance is more attractive than absolute longs here, because the policy tailwind may already be priced while litigation and supply-chain adaptation remain unresolved.